Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001779092-25-000007
Filing Date
2025-11-26
Accepted
2025-11-26 16:07:19
Documents
1
Period of Report
2025-11-24

Document Format Files

Seq Description Document Type Size
1 form4-11262025_091116.html 4  
1 form4-11262025_091116.xml 4 4799
  Complete submission text file 0001779092-25-000007.txt   6317
Mailing Address 501 CANAL BLVD. RICHMOND CA 94084
Business Address 501 CANAL BLVD. RICHMOND CA 94084 5109706000
SANGAMO THERAPEUTICS, INC (Issuer) CIK: 0001001233 (see all company filings)

EIN.: 680359556 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O SANGAMO THERAPEUTICS, INC. 501 CANAL BLVD. RICHMOND CA 94804
Business Address
Duraibabu Prathyusha (Reporting) CIK: 0001779092 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-30171 | Film No.: 251530221